Company intelligence / Profile preview
Hemoglobin Oxygen Therapeutics
Souderton, Pennsylvania, United Stateshbo2therapeutics.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
Hemopure® (hemoglobin glutamer 250 bovine) is approved in South Africa and Russia for human use as an alternative to allogeneic blood transfusion, with Oxyglobin® approved for veterinary use in the US and EU. Clinical studies show Hemopure increases tissue and organ oxygenation and may have utility in organ preservation for transplantation, but broad FDA approval for human use remains pending. Recent preclinical data indicate Hemopure restored organ function after severe ischemia in animal studies[6][9][5].
- Therapeutic areas
- CardiovascularHematology
- Modalities
- BiologicRecombinant proteinBlood component therapyMedical device
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Hemoglobin Oxygen Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hemoglobin Oxygen Therapeutics.